Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort. [PDF]
J Int AIDS SocABSTRACT Introduction Migrants living with HIV often face high mobility, vulnerability and limited baseline information on HIV‐1 genotype or treatment history. We aimed to assess the effectiveness and persistence of long‐acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) among migrants in Spain. Methods This multicentre cohort study across 58
Llenas-García J +62 more
europepmc +2 more sources
The Epidemiology of HIV-1 Resistance to Two-Drug Regimens in Multicenter Cohort From Poland-A Cross-Sectional Study. [PDF]
Health Sci RepABSTRACT Background and Aims Concerns about antiretroviral therapy failure are growing among people with HIV receiving two‐drug regimens, as these schemes include fewer active agents, while the prevalence of transmitted resistance in HIV‐1 continues to increase.
Załęski A +7 more
europepmc +2 more sources
The role of rilpivirine in Southern Africa
Southern African Journal of HIV Medicine, 2019 Rilpivirine, a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), is included as an option in first-line antiretroviral therapy (ART) for antiretroviral-naïve individuals in treatment guidelines in high-income countries, including ...
Michelle A. Moorhouse, Karen Cohen
doaj +1 more source
Optimization of diarylazines as anti-HIV agents with dramatically [PDF]
, 2013 Non-nucleoside inhibitors of HIV-1 reverse transcriptase are reported that have ca. 100-fold greater solubility than the structurally related drugs etravirine and rilpivirine, while retaining high anti-viral activity.
Anderson, Karen S. +4 more
core +1 more source
Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]
, 2015 One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A. +2 more
core +2 more sources
Preferred antiretroviral drugs for the next decade of scale up [PDF]
, 2012 Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission.
Andrieux-Meyer, Isabelle +10 more
core +4 more sources
Journal of Infection and Public Health, 2015 Summary: This paper reviews the current literature and information on the combination drug Complera™ (rilpivirine/emtricitabine/tenofovir disoproxil fumarate) that was approved by the Food and Drug Administration (FDA) in August 2011.PubMed, Cochrane and
Wissam K. Kabbara, Wijdan H. Ramadan
doaj +1 more source
How developing world concerns need to be part of drug development plans: A case study of four emerging antiretrovirals [PDF]
, 2008 Clinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries.
Alexandra Calmy +22 more
core +3 more sources
Viruses, 2022 Two-drug regimens (2DRs) are emerging in clinical practice guidelines as treatment option for both naive and treatment-experienced people living with HIV (PLHIV).
Carmen Hidalgo-Tenorio +8 more
doaj +1 more source
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. [PDF]
, 2017 Rilpivirine is safe and effective in HIV-naïve patients with low baseline HIV-RNA or in switch strategy. It offers the advantages of few drug-drug interactions and a favourable toxicity profile.
Battegay, Manuel +9 more
core +5 more sources